Procysbi® (cysteamine bitartrate) – New formulation approval
February 18, 2020 - Horizon Therapeutics announced the FDA approval of Procysbi (cysteamine bitartrate) delayed-release oral granules, for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.
Download PDF
